Know Labs, Inc. to Host Review of Second Quarter Fiscal Year 2024 Results on May 15, 2024
Know Labs, Inc. (NYSE American: KNW) will host a webcast on May 15, 2024, to review Q2 FY 2024 results. The company is focused on non-invasive medical diagnostic technology, including a continuous blood glucose monitoring device.
- None.
- None.
Media and investors may access the live audio webcast at https://ir.knowlabs.co, beginning at 1:15 pm PT. Questions to the Company’s management team can be submitted through the webcast portal during the meeting. The webcast will also be available for replay at the company’s website.
For more information on Know Labs’ diagnostic platform technology and its progress in developing the first FDA-cleared non-invasive continuous blood glucose monitoring device, visit www.knowlabs.co.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of the technology will be in a product marketed as a non-invasive glucose monitor. The device will provide the user with accessible and affordable real-time information on blood glucose levels. This product will require
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508437706/en/
For Know Labs Media Inquiries:
Matter Health
Abby Mayo
Knowlabs@matternow.com
Ph. (617) 272-0592
Know Labs, Inc.:
Jordyn Hujar
jordyn@knowlabs.co
Ph. (206) 629-6414
Source: Know Labs, Inc.
FAQ
When will Know Labs, Inc. host a review of its Q2 FY 2024 results?
What is Know Labs' stock symbol?
What does Know Labs focus on?
Where can investors access the live audio webcast?
What progress has Know Labs made in developing a non-invasive continuous blood glucose monitoring device?
